2 recruiting, 2 terminated, 1 completed, 1 unknown. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 2, Terminated 2, Completed 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow EBV: new trials by email Literature Review of EBV trials Research Report on EBV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib Combined With Selinexor for CAEBVD golidocitinib, Selinexor (combination therapy) - Lymphohistiocytosis, EBV | Phase 2 / Phase 3 | Recruiting | Beijing Friendship Hospital | 28 | 2026-01-01 | 2026-01-27 |
| PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. PD-1 antibody (SHR-1210) - Gastric Cancer Stage IV, EBV | Phase 2 | Completed | Sun Yat-sen University | 6 | 2018-12-01 | 2022-09-21 |
| Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial Valaciclovir, Placebo capsules (containing Avicel blend) - COPD, EBV | Phase 2 | Terminated | Belfast Health and Social Care Trust | 85 | 2018-10-11 | 2020-09-30 |
| Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation Chidamide BIW, Chidamide QD - Lymphoma, Extranodal NK-T-Cell, EBV | Phase 2 | Unknown | Huiqiang Huang | 24 | 2016-09-01 | 2016-08-25 |
| A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® IFN-γ positive selected T-cells - Adenovirus Infection, EBV | Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 30 | 2014-12-01 | 2025-03-20 |
| Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma baltaleucel-T - Lymphoma, Extranodal NK-T-Cell, EBV | Phase 2 | Terminated | Cell Medica Ltd | 15 | 2014-09-01 | 2019-03-13 |
Lymphoma, Extranodal NK-T-Cell (2) · Adenoviridae Infections (1) · Cytomegalovirus Infections (1) · Epstein-Barr Virus Infections (1) · Pulmonary Disease, Chronic Obstructive (1) · Stomach Neoplasms (1)
Neoplasms (3) · DNA Virus Infections (2) · Herpesviridae Infections (2) · Infections (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell (2) · Neoplasms by Histologic Type (2) · Virus Diseases (2) · Chronic Disease (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
Combined Modality Therapy (1) · Valacyclovir (1) · camrelizumab (1) · selinexor (1)
Beijing Friendship Hospital (1) · Belfast Health and Social Care Trust (1) · Cell Medica Ltd (1) · Huiqiang Huang (1) · Sun Yat-sen University (1) · University Hospital, Basel, Switzerland (1)
China (2) · United Kingdom (2) · France (1) · South Korea (1) · Switzerland (1) · United States (1)
Helen Heslop, MD (1) · Joe Kidney, MB, MD (1) · Kurt Gunter, MD (1) · Nina Khanna, Dr. (1) · Rui-Hua Xu, MD, PhD (1)